Publications

2017

Sun Q, Zhao Z. Peptide Hormones as Tumor Markers in Clinical Practice. Enzymes. 2017;42:65-79.
Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, et al. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. J Am Med Inform Assoc. 2017;24(3):513-519.
Salvatore SP, Chevalier JM, Kuo SF, Audia PF, Seshan SV. Kidney disease in patients with obesity: It is not always obesity-related glomerulopathy alone. Obes Res Clin Pract. 2017;11(5):597-606.
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. Cancer Discov. 2017;7(9):973-983.
De Robertis M, Loiacono L, Fusilli C, Poeta ML, Mazza T, Sanchez M, et al. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clin Cancer Res. 2017;23(1):159-170.
Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017;8:15107.
Posch F, Gebhart J, Rand JH, Koder S, Quehenberger P, Pengo V, et al. Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Med. 2017;15(1):54.
Mohammed KH, Siddiqui MT, Willis BC, Tsvetkova DZ, Mohamed A, Patel S, et al. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas. Appl Immunohistochem Mol Morphol. 2017;25(10):731-735.
Staunton L, Tonry C, Lis R, Espina V, Liotta L, Inzitari R, et al. Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. Mol Cancer Res. 2017;15(3):281-293.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700